Polycystic Kidney Disease Drugs Market by Type and Geography - Forecast and Analysis 2022-2026

The polycystic kidney disease drugs market share is expected to increase by USD 510.69 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 6.7%. The growth of the polycystic kidney disease drugs market is being driven by the high prevalence of chronic kidney diseases. Worldwide, around 10% of the population is affected by chronic kidney disease, and lack of access to affordable treatment results in millions of deaths annually. Polycystic kidney disease, although rare, is a significant cause of chronic kidney disease and can lead to kidney failure. As the major form of chronic kidney disease, the prevalence of polycystic kidney disease contributes significantly to the strong prevalence of chronic kidney disease. The increasing prevalence of polycystic kidney disease is, therefore, a major factor driving the growth of the market.

This polycystic kidney disease drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers polycystic kidney disease drugs market segmentation by type (ADPKD and ARPKD) and geography (North America, Europe, Asia, and Rest of World (ROW)). 

What will the Polycystic Kidney Disease Drugs Market Size be During the Forecast Period?

To learn more about the Report Download the Free Report Sample 

Who are the Major Polycystic Kidney Disease Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

• Apotex Inc.
• AstraZeneca Plc
• Dr. Reddys Laboratories Ltd.
• Galapagos NV
• Johnson and Johnson
• Merck and Co. Inc.
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Palladio Biosciences Inc.
• Reata Pharmaceuticals Inc.
• Regulus Therapeutics Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• XORTX Therapeutics Inc.

This statistical study of the PKD drugs market encompasses successful business strategies deployed by the key vendors. The polycystic kidney disease drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• AstraZeneca Plc - Under the unified segment, the company engages in the discovery, development, manufacturing, marketing, and sale of pharmaceutical products. 
• AstraZeneca Plc - The company offers polycystic kidney disease drugs such as Forxiga.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The polycystic kidney disease drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Polycystic Kidney Disease Drugs Market: Key Drivers, Trends, and Challenges

The orphan product development is the notable driving the polycystic kidney disease drugs market growth, although factors such as lack of approved drugs may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the polycystic kidney disease drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Polycystic Kidney Disease Drugs Market Driver

The US FDA's Office of Orphan Products Development is dedicated to advancing the development and evaluation of biologics, drugs, and devices for the treatment and diagnosis of rare diseases. It grants orphan status to biologics and drugs that are proven to be safe and effective in treating rare diseases and also funds clinical research through the Orphan Products Grants Program (OPGP) to assess the safety and efficacy of these treatments. In the EU, orphan drugs receive protocol assistance and ten-year market exclusivity. In the US, companies developing orphan drugs are eligible for incentives such as tax credits for clinical testing, exemption from prescription fees (unless indicated for additional non-orphan indications), and market exclusivity for seven years, during which the entry of generics is prohibited, thus protecting the market sales of orphan drugs.These special regulatory designations can help accelerate the approval and launch of new treatments, which is expected to drive market growth in the forecast period.

Key Polycystic Kidney Disease Drugs Market Trend

Increasing research funding is one of the key polycystic kidney disease (PKD) drugs market trends propelling the market growth. Fundamentally, polycystic kidney disease is a hereditary disease, which cannot be cured completely due to the lack of approved drugs. Despite the increasing prevalence of the disease, the market is witnessing a huge unmet need for therapeutics. This is leading various vendors and research institutes to research developing novel therapies. However, the market faces a challenge, as a major share of the vendors and research institutes that are conducting research are either small- or mid-sized companies, which lack funding to successfully conduct the research. As a result, these vendors and organizations rely on grants from organizations that provide research funding to complete their clinical trial research and launch the drug in the market. Meanwhile, there are a number of organizations that provide research funding, which is fueling the market growth.

Key Polycystic Kidney Disease Drugs Market Challenge

The lack of approved drugs is one of the key factors limiting the polycystic kidney disease drugs market growth. Unfortunately, the market has only one approved branded drug. Currently, the market is heavily dominated by the off-label use of various antibiotics, drugs treating hypertension, and NSAIDs to treat certain symptoms. Well, the symptomatic treatment of off-label drugs leads to limited patient adherence to the treatment with these drugs, as they provide only temporary relief from the symptoms and do not stop the progression of the disease. Moreover, the market faces a heavy threat from the increasing number of generic versions of various off-label drugs. Thus, the dominance of generics is expected to lead to value erosion in the market, and the lack of approved therapies is expected to continue to hinder the growth of the global polycystic kidney disease drugs market during the forecast period.

This polycystic kidney disease drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Which are the Key Regions for Polycystic Kidney Disease Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the polycystic kidney disease drugs market in North America. Market growth in this region will be slower than the growth of the market in Asia.

Advances in the R&D of PKD will facilitate the polycystic kidney disease drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 negatively impacted the market in focus in this region. However, in 2021, with the large-scale vaccination drives and the resumption of operations in the healthcare units, higher inflows of patients started resuming their polycystic kidney disease treatments in healthcare facilities in this region as compared with 2020. Thus, the increased requirements for novel drugs from the healthcare facilities will lead to the increased production of polycystic kidney disease drugs in the region, which will help the market in focus in North America to witness significant growth during the forecast period.

What are the Revenue-generating Type Segments in the Polycystic Kidney Disease Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The polycystic kidney disease drugs market share growth by the ADPKD segment will be significant during the forecast period. Most people with ADPKD have defects in the polycystic kidney disease 1 gene, and about one out of six or seven people with ADPKD have a defective polycystic kidney disease 2 gene. Moreover, ADPKD is the most common form of polycystic kidney disease. The prevalence of ADPKD ranges from one in every 400 to 1,000 people globally. Thus, the increasing cases of ADPKD will propel the market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the PKD drugs market size and actionable market insights on post COVID-19 impact on each segment.

Polycystic Kidney Disease Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the PKD drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

You may be interested in:

Kidney Transplantation Therapeutics market - The market share is expected to reach an estimated value of USD 1.16 billion by 2026 at an accelerating CAGR of 4.32%.

Kidney Stones market - The market share is expected to increase by USD 416.09 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.69%.

Polycystic Kidney Disease Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 6.7%
Market growth 2022-2026	$ 510.69 million
Market structure	Fragmented
YoY growth (%)	5.11
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Apotex Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Galapagos NV, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Reata Pharmaceuticals Inc., Regulus Therapeutics Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and XORTX Therapeutics Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Polycystic Kidney Disease Drugs Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive polycystic kidney disease drugs market growth during the next five years
• Precise estimation of the polycystic kidney disease drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the polycystic kidney disease drugs industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of polycystic kidney disease drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch